Open-angle glaucoma (OAG) - market—2028

Von Willebrand Disease (VWD)market2028 report deliver an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Von Willebrand Disease (VWD) in the United States, EU5 (Germany, France, Italy, Spain , and the United Kingdom), and Japan.
Von Willebrand disease is the most common inherited bleeding disorder in the United States, affecting as many as 1 in every 1000 individuals. Von Willebrand disease is often compared to hemophilia, but it is a different condition and has a different pattern of bleeding. It affects both boys and girls equally (while hemophilia mainly affects boys). A parent with VWD has a 50% chance of passing the gene to his or her child.
Our forecasting model has defined the diagnosed prevalent population of Von Willebrand Disease in children and adults. In the US population, people belonging to the latter half of the first decade and the early first half of the second-decade life (i.e., 018 years) reported higher diagnosed prevalence than that of people belonging to other age groups. Whereas, in the German population, people belonging to the age group of 1944 years reported higher diagnosed prevalence than that of people belonging to other age groups.
Geography Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 20172028
Von Willebrand Disease (VWD)Disease Understanding and Treatment Algorithm
Von Willebrand disease (VWD) is a genetic disorder caused by missing or defective von Willebrand factor (VWF), a clotting protein. VWF binds factor VIII, a key clotting protein, and platelets in blood vessel walls, which help form a platelet plug during the clotting process.
Von Willebrand disease is a heterogeneous disorder and is usually classified into two main types, according to inheritance or acquired forms. Inherited forms are further subdivided into Type 1, 2, and 3 along with a pseudo-VWD. Platelet type disorder which in turn describes their pathophysiology. Type 1 is easily distinguished from type 3 by its milder deficiency and is characterized by a decreased quantity of vWF whereas Type 2 is distinguished on the basis of functional or qualitative deficiencies.
Von Willebrand Disease (VWD) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent Population of Von Willebrand disease (VWD) in 7MM, Gender-Specific Diagnosed Prevalent Population of Von Willebrand disease (VWD) in 7MM, Type-specific Diagnosed Prevalent Cases of Von Willebrand disease (VWD) in 7MM, and Age-specific Diagnosed Prevalent Cases of Von Willebrand disease (VWD) in 7MM) scenario of Von Willebrand disease (VWD) in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain , and the United Kingdom) and Japan from 2017 to 2028.
According to DelveInsight, the total diagnosed prevalent population of Von Willebrand disease (VWD) in seven major markets was 33,758 in 2017. The number of Von Willebrand disease (VWD) cases in the 7MM is expected to increase during the study period of 20172028.
Von Willebrand disease (VWD) Drug Chapters
The current therapeutic landscape of Von Willebrand disease can be divided into three major categories based on the class of drugs administered, they are; Non-replacement Therapy using desmopressin (DDAVP) to increase the plasma concentration of vWF, Replacement Therapy using plasma-derived coagulation factor concentrates (Humate-P, Alphanate, Immunate, and Wilate), and Adjunct Therapy using primarily anti-fibrinolytics, such as Tranexamic Acid (Cyclokapron).
A new category of recombinant coagulation factor concentrates -Vonvendi (Shire) has recently entered the replacement therapy segment. The approved (and their generic versions) as well as off-label products that are being used for the treatment of von Willebrand Disease, and contributing toward the market revenue, belong to either of these above-mentioned therapeutic classes.
Non-replacement therapy includes Desmopressin, which has been used as the first-line of treatment mostly for patients suffering from the Type 1 variants and a few Type-2 cases. Stimate (CSL Behring GmbH), DDAVP (Sanofi-Aventis), and Octostim (CSL Behring GmbH) with desmopressin acetate being the active ingredient are some of the drugs which belong to this category. The gradual emergence of virally-inactivated FVIII concentrates containing VWF for the treatment of hemophilia A proved a more optimal replacement therapeutic option for patients with VWD. Currently, they form the second-line of treatment especially during severe bleeding episodes of Type 1 variant as well as Type 2 and Type 3. In the United States, VWD is typically treated with either Humate-P (CSL Behring) or Wilate (Octapharma) or Alphanate (Grifols), which is identical to Fanhdi, made in Spain. Adjunct or supportive therapies mainly include antifibrinolytic agents, such as tranexamic acid (Cyclokapron) and amiococaproic acid (Amicar) which work by inhibiting the interaction of plasminogen with fibrin, thus preventing the degradation of the fibrin clot.

Von Willebrand disease (VWD) Market Outlook
According to DelveInsight, the market of Von Willebrand disease (VWD) in 7MM was found to be approximately USD 397.20 million in 2017. Among the EU5 countries, the United Kingdom had the highest market size with USD 61.62 million in 2017, while Spain had the lowest market size of Von Willebrand Disease with USD 6.37 million in 2017.
Von Willebrand disease (VWD) Drugs Uptake
Overall, the increasing diagnosed prevalence of the disease along with the promising expanded recombinant therapies will fuel the market during the forecasted period of 20192028 with some of the major players in the VWD treatment market being Shire Plc. (earlier Baxalta), CSL Behring, LFB Biomedicaments SA, Octapharma AG, and Grifols SA.
The recent launch of Shires Vonvendi/Veyvondi in the US and the expected launch in EU in 2019 have the potential to create a significant positive shift in the von Willebrand Disease market size. Expected launch of Wilfactin (LFB Biomedicaments) in 2021 (will file in the US) will also create a positive impact on the VWD market in US.

Von Willebrand disease (VWD) Report Insights
Patient Population by total diagnosed cases
Gender-specific diagnosed population
Type-specific diagnosed population
Age-specific diagnosed population
Therapeutic Approaches
Pipeline Analysis
Market Size and Trends
Market Opportunities
Impact of upcoming Therapies
Von Willebrand disease (VWD) Report Key Strengths
10-Year Forecast
7MM Coverage
Epidemiology Segmentation
Drugs Uptake
Highly Analyzed Market
Key Cross Competition
Von Willebrand disease (VWD) Report Assessment
Current Treatment Practices
Unmet Needs
Detailed Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers
Key Benefits
This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Von Willebrand disease (VWD) market.
Organize sales and marketing efforts by identifying the best opportunities for Von Willebrand disease (VWD) market.
To understand the future market competition in the Von Willebrand disease (VWD) market.

List Of Tables

Table 1 Classification of von Willebrand disease
Table 2 Sub-Classification of von Willebrand disease Type 2A
Table 3 Level of Evidence
Table 4 Total Diagnosed Prevalent Patient Population of Von Willebrand Disease in the 7MM (20172028)
Table 5 Total Diagnosed Prevalent Population of Von Willebrand Disease in the United States (20172028)
Table 6 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (20172028)
Table 7 Type Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (20172028)
Table 8 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (20172028)
Table 9 Total Diagnosed Prevalent Population of Von Willebrand Disease in Germany (20172028)
Table 10 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (20172028)
Table 11 Type Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (20172028)
Table 12 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (20172028)
Table 13 Total Diagnosed Prevalent Population of Von Willebrand Disease in France (20172028)
Table 14 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in France (20172028)
Table 15 Type Specific Diagnosed Prevalence of Von Willebrand Disease in France (20172028)
Table 16 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in France (20172028)
Table 17 Total Diagnosed Prevalent Population of Von Willebrand Disease in Italy (20172028)
Table 18 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (20172028)
Table 19 Type Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (20172028)
Table 20 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (20172028)
Table 21 Total Diagnosed Prevalent Population of Von Willebrand Disease in Spain (20172028)
Table 22 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (20172028)
Table 23 Type Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (20172028)
Table 24 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (20172028)
Table 25 Total Diagnosed Prevalent Population of Von Willebrand Disease in the UK (20172028)
Table 26 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (20172028)
Table 27 Type-Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (20172028)
Table 28 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (20172028)
Table 29 Total Diagnosed Prevalent Population of Von Willebrand Disease in Japan (20172028)
Table 30 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (20172028)
Table 31 Type-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (20172028)
Table 32 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (20172028)
Table 33 Treatment of von Willebrand Disease
Table 34 Indications for Replacement Therapy in VWD
Table 35 List of Marketed Drugs Analysis
Table 36 List of Other Plasma Derived Products
Table 37 Vonvendi, Clinical Trial Description, 2019
Table 38 Voncento, Clinical Trial Description, 2019
Table 39 Wilate, Clinical Trial Description, 2019
Table 40 7 Major Market Size of Von Willebrand Disease in USD Million (20172028)
Table 41 Market size by therapies of Von Willebrand Disease by therapies in 7MM, in USD Million (20172028)
Table 42 United States Market Size of Von Willebrand Disease in USD Million (20172028)
Table 43 Market size of Von Willebrand Disease by therapies in the United States, in USD Million (20172028)
Table 44 Market Size of Von Willebrand Disease in Germany, in USD Million (20172028)
Table 45 Market size of Von Willebrand Disease by therapies in Germany, in USD Million (20172028)
Table 46 Market Size of Von Willebrand Disease in France, in USD Million (20172028)
Table 47 Market size of Von Willebrand Disease by therapies in France, in USD Million (20172028)
Table 48 Market Size of Von Willebrand Disease in Italy, in USD Million (20172028)
Table 49 Market size of Von Willebrand Disease by therapies in Italy, in USD Million (20172028)
Table 50 Market Size of Von Willebrand Disease in Spain, in USD Million (20172028)
Table 51 Market size of Von Willebrand Disease by therapies in Spain, in USD Million (20172028)
Table 52 Market Size of Von Willebrand Disease in the UK, in USD Million (20172028)
Table 53 Market size of Von Willebrand Disease by therapies in the UK, in USD Million (20172028)
Table 54 Market Size of Von Willebrand Disease in Japan, in USD Million (20172028)
Table 55 Market size of Von Willebrand Disease by therapies in Japan, in USD Million (20172028)

List Of Figures

Figure 1 The structure of VWF
Figure 2 Biosynthesis and Function of von Willebrand Factor
Figure 3 Symptoms of Subtypes of Type 2
Figure 4 Biosynthesis and Function of von Willebrand Factor
Figure 5 Type 2 VWD Variants.
Figure 6 Structure and function of pre-pro VWF
Figure 7 Pathophysiological Mechanisms and Classification of von Willebrand Disease
Figure 8 Initial hemostasis laboratory evaluation
Figure 9 Algorithm proposed for the diagnosis and classification of VWD
Figure 10 Total Diagnosed Prevalent Population of Von Willebrand Disease in the 7MM (20172028)
Figure 11 Diagnosed Prevalence of Von Willebrand Disease in the United States (20172028)
Figure 12 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (20172028)
Figure 13 Type Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (20172028)
Figure 14 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (20172028)
Figure 15 Total Diagnosed Prevalent Population of Von Willebrand Disease in Germany (20172028)
Figure 16 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (20172028)
Figure 17 Type Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (20172028)
Figure 18 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (20172028)
Figure 19 Total Diagnosed Prevalent Population of Von Willebrand Disease in France (20172028)
Figure 20 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in France (20172028)
Figure 21 Type Specific Diagnosed Prevalence of Von Willebrand Disease in France (20172028)
Figure 22 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in France (20172028)
Figure 23 Total Diagnosed Prevalent Population of Von Willebrand Disease in Italy (20172028)
Figure 24 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (20172028)
Figure 25 Type Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (20172028)
Figure 26 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (20172028)
Figure 27 Total Diagnosed Prevalent Population of Von Willebrand Disease in Spain (20172028)
Figure 28 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (20172028)
Figure 29 Type Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (20172028)
Figure 30 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (20172028)
Figure 31 Total Diagnosed Prevalent Population of Von Willebrand Disease in the UK (20172028)
Figure 32 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (20172028)
Figure 33 Type-Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (20172028)
Figure 34 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (20172028)
Figure 35 Total Diagnosed Prevalent Population of Von Willebrand Disease in Japan (20172028)
Figure 36 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (20172028)
Figure 37 Type-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (20172028)
Figure 38 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (20172028)
Figure 39 Treatment scheme for Von Willebrand Disease
Figure 40 Unmet Needs of Von Willebrand Disease
Figure 41 Marketed Drugs
Figure 42 7 Major Market Size of Von Willebrand Disease in USD Million (20172028)
Figure 43 7 Major Market Size by therapies of Von Willebrand Disease in USD Million (20172028)
Figure 44 Market Size of Von Willebrand Disease in the United States, USD Millions (20172028)
Figure 45 Market size of Von Willebrand Disease by therapies in the US, in USD Million (20172028)
Figure 46 Market Size of Von Willebrand Disease in Germany, USD Millions (20172028)
Figure 47 Market Size of Von Willebrand Disease by therapies, in Germany, in USD Million (20172028)
Figure 48 Market Size of Von Willebrand Disease in France, USD Millions (20172028)
Figure 49 Market Size of Von Willebrand Disease by therapies, in France, in USD Million (20172028)
Figure 50 Market Size of Von Willebrand Disease in Italy, USD Millions (20172028)
Figure 51 Market Size of Von Willebrand Disease by therapies in Italy, in USD Million (20172028)
Figure 52 Market Size of Von Willebrand Disease in Spain, USD Millions (20172028)
Figure 53 Market Size of Von Willebrand Disease by therapies in Spain, in USD Million (20172028)
Figure 54 Market Size of Von Willebrand Disease in the UK, USD Millions (20172028)
Figure 55 Market Size of Von Willebrand Disease by therapies in the UK, in USD Million (20172028)
Figure 56 Market Size of Von Willebrand Disease in Japan, USD Millions (20172028)
Figure 57 Market Size of Von Willebrand Disease by therapies in Japan, in USD Million (20172028)
Figure 58 Market Drivers
Figure 59 Market Barriers

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available